1867 related articles for article (PubMed ID: 30561868)
21. Testing the 2018 NIA-AA research framework in a retrospective large cohort of patients with cognitive impairment: from biological biomarkers to clinical syndromes.
Carandini T; Arighi A; Sacchi L; Fumagalli GG; Pietroboni AM; Ghezzi L; Colombi A; Scarioni M; Fenoglio C; De Riz MA; Marotta G; Scarpini E; Galimberti D
Alzheimers Res Ther; 2019 Oct; 11(1):84. PubMed ID: 31615545
[TBL] [Abstract][Full Text] [Related]
22. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
[TBL] [Abstract][Full Text] [Related]
23. Erlangen Score Predicts Cognitive and Neuroimaging Progression in Mild Cognitive Impairment Stage of Alzheimer's Disease.
Skillbäck T; Kornhuber J; Blennow K; Zetterberg H; Lewczuk P;
J Alzheimers Dis; 2019; 69(2):551-559. PubMed ID: 31104027
[TBL] [Abstract][Full Text] [Related]
24. Discordant amyloid-β PET and CSF biomarkers and its clinical consequences.
de Wilde A; Reimand J; Teunissen CE; Zwan M; Windhorst AD; Boellaard R; van der Flier WM; Scheltens P; van Berckel BNM; Bouwman F; Ossenkoppele R
Alzheimers Res Ther; 2019 Sep; 11(1):78. PubMed ID: 31511058
[TBL] [Abstract][Full Text] [Related]
25. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
[TBL] [Abstract][Full Text] [Related]
26. Association of Klotho-VS Heterozygosity With Risk of Alzheimer Disease in Individuals Who Carry APOE4.
Belloy ME; Napolioni V; Han SS; Le Guen Y; Greicius MD;
JAMA Neurol; 2020 Jul; 77(7):849-862. PubMed ID: 32282020
[TBL] [Abstract][Full Text] [Related]
27. Psychometric Properties of Alzheimer's Disease Assessment Scale-Cognitive Subscale for Mild Cognitive Impairment and Mild Alzheimer's Disease Patients in an Asian Context.
Zainal NH; Silva E; Lim LL; Kandiah N
Ann Acad Med Singap; 2016 Jul; 45(7):273-83. PubMed ID: 27523508
[TBL] [Abstract][Full Text] [Related]
28. Enriching amnestic mild cognitive impairment populations for clinical trials: optimal combination of biomarkers to predict conversion to dementia.
Yu P; Dean RA; Hall SD; Qi Y; Sethuraman G; Willis BA; Siemers ER; Martenyi F; Tauscher JT; Schwarz AJ
J Alzheimers Dis; 2012; 32(2):373-85. PubMed ID: 22796873
[TBL] [Abstract][Full Text] [Related]
29. Quantitative Radiomic Features as New Biomarkers for Alzheimer's Disease: An Amyloid PET Study.
Ding Y; Zhao K; Che T; Du K; Sun H; Liu S; Zheng Y; Li S; Liu B; Liu Y;
Cereb Cortex; 2021 Jul; 31(8):3950-3961. PubMed ID: 33884402
[TBL] [Abstract][Full Text] [Related]
30. Comparison of Visual and Quantitative Florbetapir F 18 Positron Emission Tomography Analysis in Predicting Mild Cognitive Impairment Outcomes.
Schreiber S; Landau SM; Fero A; Schreiber F; Jagust WJ;
JAMA Neurol; 2015 Oct; 72(10):1183-90. PubMed ID: 26280102
[TBL] [Abstract][Full Text] [Related]
31. Cerebrospinal fluid synaptosomal-associated protein 25 is a key player in synaptic degeneration in mild cognitive impairment and Alzheimer's disease.
Zhang H; Therriault J; Kang MS; Ng KP; Pascoal TA; Rosa-Neto P; Gauthier S;
Alzheimers Res Ther; 2018 Aug; 10(1):80. PubMed ID: 30115118
[TBL] [Abstract][Full Text] [Related]
32. Plasma amyloid assay as a pre-screening tool for amyloid positron emission tomography imaging in early stage Alzheimer's disease.
Lin SY; Lin KJ; Lin PC; Huang CC; Chang CC; Lee YC; Hsiao IT; Yen TC; Huang WS; Yang BH; Wang PN
Alzheimers Res Ther; 2019 Dec; 11(1):111. PubMed ID: 31881963
[TBL] [Abstract][Full Text] [Related]
33. A data-driven model of biomarker changes in sporadic Alzheimer's disease.
Young AL; Oxtoby NP; Daga P; Cash DM; Fox NC; Ourselin S; Schott JM; Alexander DC;
Brain; 2014 Sep; 137(Pt 9):2564-77. PubMed ID: 25012224
[TBL] [Abstract][Full Text] [Related]
34. Accurate risk estimation of β-amyloid positivity to identify prodromal Alzheimer's disease: Cross-validation study of practical algorithms.
Palmqvist S; Insel PS; Zetterberg H; Blennow K; Brix B; Stomrud E; ; ; Mattsson N; Hansson O
Alzheimers Dement; 2019 Feb; 15(2):194-204. PubMed ID: 30365928
[TBL] [Abstract][Full Text] [Related]
35. Amyloid cascade and tau pathology cerebrospinal fluid markers in mild cognitive impairment with regards to Alzheimer's disease cerebral metabolic signature.
Alexopoulos P; Guo LH; Jiang M; Bujo H; Grimmer T; Förster S; Drzezga A; Kurz A; Perneczky R
J Alzheimers Dis; 2013; 36(2):401-8. PubMed ID: 23609762
[TBL] [Abstract][Full Text] [Related]
36. Prediction of fast decline in amyloid positive mild cognitive impairment patients using multimodal biomarkers.
Jang H; Park J; Woo S; Kim S; Kim HJ; Na DL; Lockhart SN; Kim Y; Kim KW; Cho SH; Kim SJ; Seong JK; Seo SW;
Neuroimage Clin; 2019; 24():101941. PubMed ID: 31376643
[TBL] [Abstract][Full Text] [Related]
37. [Validation of the Hungarian version of Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) in patients with mild cognitive impairment].
Papp E; Pákáski M; Drótos G; Kálmán J
Psychiatr Hung; 2012; 27(6):426-34. PubMed ID: 23429337
[TBL] [Abstract][Full Text] [Related]
38. Association of Cerebral Amyloid-β Aggregation With Cognitive Functioning in Persons Without Dementia.
Jansen WJ; Ossenkoppele R; Tijms BM; Fagan AM; Hansson O; Klunk WE; van der Flier WM; Villemagne VL; Frisoni GB; Fleisher AS; Lleó A; Mintun MA; Wallin A; Engelborghs S; Na DL; Chételat G; Molinuevo JL; Landau SM; Mattsson N; Kornhuber J; Sabri O; Rowe CC; Parnetti L; Popp J; Fladby T; Jagust WJ; Aalten P; Lee DY; Vandenberghe R; Resende de Oliveira C; Kapaki E; Froelich L; Ivanoiu A; Gabryelewicz T; Verbeek MM; Sanchez-Juan P; Hildebrandt H; Camus V; Zboch M; Brooks DJ; Drzezga A; Rinne JO; Newberg A; de Mendonça A; Sarazin M; Rabinovici GD; Madsen K; Kramberger MG; Nordberg A; Mok V; Mroczko B; Wolk DA; Meyer PT; Tsolaki M; Scheltens P; Verhey FRJ; Visser PJ; ; Aarsland D; Alcolea D; Alexander M; Almdahl IS; Arnold SE; Baldeiras I; Barthel H; van Berckel BNM; Blennow K; van Buchem MA; Cavedo E; Chen K; Chipi E; Cohen AD; Förster S; Fortea J; Frederiksen KS; Freund-Levi Y; Gkatzima O; Gordon MF; Grimmer T; Hampel H; Hausner L; Hellwig S; Herukka SK; Johannsen P; Klimkowicz-Mrowiec A; Köhler S; Koglin N; van Laere K; de Leon M; Lisetti V; Maier W; Marcusson J; Meulenbroek O; Møllergård HM; Morris JC; Nordlund A; Novak GP; Paraskevas GP; Perera G; Peters O; Ramakers IHGB; Rami L; Rodríguez-Rodríguez E; Roe CM; Rot U; Rüther E; Santana I; Schröder J; Seo SW; Soininen H; Spiru L; Stomrud E; Struyfs H; Teunissen CE; Vos SJB; van Waalwijk van Doorn LJC; Waldemar G; Wallin ÅK; Wiltfang J; Zetterberg H
JAMA Psychiatry; 2018 Jan; 75(1):84-95. PubMed ID: 29188296
[TBL] [Abstract][Full Text] [Related]
39. Plasma Aβ42/40 ratio alone or combined with FDG-PET can accurately predict amyloid-PET positivity: a cross-sectional analysis from the AB255 Study.
Pérez-Grijalba V; Arbizu J; Romero J; Prieto E; Pesini P; Sarasa L; Guillen F; Monleón I; San-José I; Martínez-Lage P; Munuera J; Hernández I; Buendía M; Sotolongo-Grau O; Alegret M; Ruiz A; Tárraga L; Boada M; Sarasa M;
Alzheimers Res Ther; 2019 Dec; 11(1):96. PubMed ID: 31787105
[TBL] [Abstract][Full Text] [Related]
40. Relationship Between Body Mass Index, ApoE4 Status, and PET-Based Amyloid and Neurodegeneration Markers in Amyloid-Positive Subjects with Normal Cognition or Mild Cognitive Impairment.
Blautzik J; Kotz S; Brendel M; Sauerbeck J; Vettermann F; Winter Y; Bartenstein P; Ishii K; Rominger A;
J Alzheimers Dis; 2018; 65(3):781-791. PubMed ID: 28697560
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
